Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02680535 · ClinicalTrials.gov registry record · NA
MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue
A NA study of Neoplasms of the Prostate, sponsored by Nanospectra Biosciences.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 5
- Study locations
NCT02680535: Completed NA study of Neoplasms of the Prostate, sponsored by Nanospectra Biosciences.
NCT02680535 is a NA study of Neoplasms of the Prostate that has completed, run by Nanospectra Biosciences. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02680535, a NA study of Neoplasms of the Prostate, has completed, sponsored by Nanospectra Biosciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 5
- Study locations
Study Summary
To determine the efficacy of using MRI/US fusion imaging technology to direct focal ablation of prostate tissue using nanoparticle-directed laser irradiation.
Primary Outcome
Efficacy of focal ablation will be assessed by 3T MRI/Ultrasound guided biopsy at 3 months after treatment. Focal ablation of clinically significant targeted prostate lesions(s) as confirmed with negative biopsies with minimal damage to surrounding healthy tissue.
Conditions Studied
Interventions
- DEVICE AuroShell particle infusion
Study Locations (5)
Texas
- The University of Texas Medical Branch - Galveston
- University of Texas Medical School at Houston - Houston
Maryland
- Johns Hopkins Hospital - Baltimore
Michigan
- University of Michigan - Ann Arbor
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2016-02 |
| Est. Completion | 2020-10 |
| Phase | NA |
What the finished NCT02680535 record still lists
NCT02680535 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Neoplasms of the Prostate appearing as the primary indexed condition, and to 1 intervention - of which AuroShell particle infusion is the first listed.
NCT02680535 lists 5 locations in 4 states (Texas, Maryland, Michigan).
Frequently Asked Questions
What is clinical trial NCT02680535 about?
NCT02680535 is a clinical study titled "MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue". To determine the efficacy of using MRI/US fusion imaging technology to direct focal ablation of prostate tissue using nanoparticle-directed laser irradiation.
What is the current status of trial NCT02680535?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2016-02. Estimated completion is 2020-10.
What conditions does trial NCT02680535 study?
This clinical trial studies the following conditions: Neoplasms of the Prostate.
What interventions are being tested in trial NCT02680535?
The interventions under investigation include: AuroShell particle infusion (DEVICE).
Who is sponsoring clinical trial NCT02680535?
This trial is sponsored by Nanospectra Biosciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02680535 being conducted?
This trial has 5 study locations across Maryland, Michigan, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02680535's enrollment target sits among peer trials
45 1411th of 2000 higher than 578 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia